Search

Results from a large phase III clinical trial unveiled at this year’s ASCO meeting identify an effective targeted therapy for a subset of people with pancreatic cancer.

… Sunday, June 2, 2019 Summary The results of a phase III trial presented on June 2 at the annual meeting of the American Society of Clinical Oncology (ASCO) show that a targeted drug called a PARP inhibitor benefits people with a BRCA mutation and pancreatic cancer that has spread. Pancreatic cancer that

Patients with high-grade epithelial ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking surgery (PDS), according to a retrospective study by Memorial Sloan Kettering Cancer Center (MSK) Team Ovary.

… Tuesday, September 5, 2023 Patients with high-grade epithelial  ovarian cancer with recurrence after neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) had similar outcomes following secondary cytoreduction surgery (SCS) compared to patients with recurrence after primary debulking

A glimpse into the world of two Gerstner Sloan Kettering Graduate School students.

… Sunday, March 1, 2009 Summary A glimpse into the world of two Gerstner Sloan Kettering Graduate School students. On January 13, Armine Matevossian , a first-year student at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences , was already in the second week of her second laboratory rotation

Learn about how our donor community is funding life-changing cancer research at Memorial Sloan Kettering and ensuring a brighter future for people with cancer around the world.

… Friday, October 1, 2021 Every day, your dollars are accelerating today’s most daring discoveries straight into lifesaving care. Read more to learn about your impact. The Society’s 2021–2022 Campaign The Society of Memorial Sloan Kettering has supported cancer research, patient care, and education at

Dr. Marks was a towering figure who left a profound legacy.

… Friday, May 8, 2020 Summary Former Memorial Sloan Kettering President Paul Marks, who died April 28, 2020, was influential in shaping modern cancer research. He will be remembered as an inspiring researcher, dedicated mentor, and visionary leader. As a young physician in the 1950s, Paul Marks was fascinated

MSK’s fertility experts and nurse specialists counsel more than 800 patients every year. Their guidance gives patients hope that they can have a family — and helps them focus on the future.

… Friday, October 1, 2021 First came the news that Lauren Heuchling had a rare, life-threatening pediatric blood disorder . Her Memorial Sloan Kettering Cancer Center doctor, Farid Boulad, said she needed grueling treatment right away: chemotherapy and radiation, followed by a bone marrow transplant. Then

Learn about recent research led by MSK physician-scientist Luc Morris, who is trying to better predict who will benefit from immunotherapy.

… Thursday, November 4, 2021 How can oncologists better predict who will benefit from a widely used class of immunotherapy drugs called checkpoint inhibitors? In the precision medicine era of cancer care, it’s a question that has only increased in relevance. To answer it, a team including Luc Morris ,

Collaboration leads to a new digital pathology tool that allows some doctors to diagnose patient tumors from home.

… Monday, September 21, 2020 Summary MSK’s Pathology Department has developed new digital technologies to keep its workers safe without having to compromise patient care — allowing some of its doctors to work from home. During the COVID-19 pandemic, Memorial Sloan Kettering doctors and nurses have been

Learn about larotrectinib, the first cancer drug to be FDA approved for adult and pediatric patients at the same time.

… Monday, November 26, 2018 Summary Larotrectinib is the first cancer drug to be FDA approved based on its effect on a specific mutation in a tumor. The US Food and Drug Administration has approved the drug larotrectinib (Vitrakvi®; LOXO-101) for cancers caused by a genetic mutation called a TRK fusion

This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be misread as mutations in the tumor, which can potentially affect the therapies patients receive. Data presented at the annual meeting of the American Society of Clinical Oncology by Ahmet Zehir, PhD, Director of Clinical Bioinformatics at Memorial Sloan Kettering Cancer Center (MSK) was simultaneously published in JAMA Oncology on June 5.

… Tuesday, June 5, 2018 Bottom Line: This study demonstrates how clonal hematopoiesis (CH)–derived mutations could lead to erroneous reporting and treatment recommendations when tumor-only sequencing is employed. If data about the blood are not part of test results, mutations present in the blood may be